InnoCare Pharma (FRA:33C) Total Liabilities : €351.69 Mil (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is InnoCare Pharma Total Liabilities?

InnoCare Pharma's Total Liabilities for the quarter that ended in Dec. 2023 was €351.69 Mil.

InnoCare Pharma's quarterly Total Liabilities declined from Jun. 2023 (€346.47 Mil) to Sep. 2023 (€341.48 Mil) but then increased from Sep. 2023 (€341.48 Mil) to Dec. 2023 (€351.69 Mil).

InnoCare Pharma's annual Total Liabilities increased from Dec. 2021 (€241.58 Mil) to Dec. 2022 (€362.46 Mil) but then declined from Dec. 2022 (€362.46 Mil) to Dec. 2023 (€351.69 Mil).

InnoCare Pharma Total Liabilities Historical Data

The historical data trend for InnoCare Pharma's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

InnoCare Pharma Total Liabilities Chart

InnoCare Pharma Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Liabilities

Get a 7-Day Free Trial

713.90

173.12

241.58

362.46

351.69

InnoCare Pharma Quarterly Data
	Dec17	Sep18	Dec18	Jun19	Sep19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Sep22	Dec22	Jun23	Sep23	Dec23	Mar24
Total Liabilities	Get a 7-Day Free Trial												362.46	346.47	341.48	351.69	-

InnoCare Pharma Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

InnoCare Pharma's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	268.927	+	(8.983	+	73.78
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	351.69

Total Liabilities	=	Total Assets (A: Dec. 2023 )	-	Total Equity (A: Dec. 2023 )
	=	1273.892	-	922.202
	=	351.69

InnoCare Pharma's Total Liabilities for the quarter that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	268.927	+	(8.983	+	73.78
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	351.69

Total Liabilities	=	Total Assets (Q: Dec. 2023 )	-	Total Equity (Q: Dec. 2023 )
	=	1273.892	-	922.202
	=	351.69

InnoCare Pharma Total Liabilities Related Terms

Thank you for viewing the detailed overview of InnoCare Pharma's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

InnoCare Pharma (FRA:33C) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » InnoCare Pharma Ltd (FRA:33C) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

09969:Hong Kong 33C:Germany 688428:China

Address

No. 8 Life Science Park Road, Building 8, Zhongguancun Life Science Park, Changping District, Beijing, CHN, 102206

Website

https://www.innocarepharma.com

InnoCare Pharma Ltd is a commercial-stage biopharmaceutical company. It discovers, develops, and commercializes drugs for the treatment of cancer and autoimmune diseases. The company's main product pipeline includes orelabrutinib, ibrutinib, zanubrutinib, tafasitamab, ICP-490, ICP-B02, ICP-248, ICP-192, ICP-723, and ICP-189, among others. Its products are mainly used to treat hematological tumors, solid tumors, and autoimmune diseases. The company is also developing products for the treatment of autoimmune diseases caused by abnormal B-cell or T-cell function.

InnoCare Pharma (FRA:33C) Headlines

No Headlines